Q32 Bio Inc.

NasdaqCM:QTTB Stock Report

Market Cap: US$96.1m

Q32 Bio Valuation

Is QTTB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of QTTB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate QTTB's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate QTTB's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QTTB?

Key metric: As QTTB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for QTTB. This is calculated by dividing QTTB's market cap by their current earnings.
What is QTTB's PE Ratio?
PE Ratio2.8x
EarningsUS$33.24m
Market CapUS$96.14m

Price to Earnings Ratio vs Peers

How does QTTB's PE Ratio compare to its peers?

The above table shows the PE ratio for QTTB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average5.9x
FBIO Fortress Biotech
0.8x-73.29%US$88.0m
AGEN Agenus
2x-48.42%US$130.8m
PLX Protalix BioTherapeutics
10.7x-69.59%US$161.9m
SPRO Spero Therapeutics
10.2xn/aUS$152.3m
QTTB Q32 Bio
2.8x-14.20%US$96.1m

Price-To-Earnings vs Peers: QTTB is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (5.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does QTTB's PE Ratio compare vs other companies in the US Biotechs Industry?

13 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.16.1x25.4%
QTTB Q32 Bio
 2.8x-14.20%US$96.14m
RIGL Rigel Pharmaceuticals
1.5x-33.25%US$533.23m
ENLV Enlivex
0.1x-147.76%US$169.58m
QTTB 2.8xIndustry Avg. 16.1xNo. of Companies13PE01632486480+
13 CompaniesEstimated GrowthMarket Cap
Industry Avg.16.1x25.4%
QTTB Q32 Bio
 2.8x-14.20%US$96.14m
No more companies

Price-To-Earnings vs Industry: QTTB is good value based on its Price-To-Earnings Ratio (2.8x) compared to the US Biotechs industry average (16.2x).

Price to Earnings Ratio vs Fair Ratio

What is QTTB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QTTB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.8x
Fair PE Ratio9x

Price-To-Earnings vs Fair Ratio: QTTB is good value based on its Price-To-Earnings Ratio (2.8x) compared to the estimated Fair Price-To-Earnings Ratio (9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QTTB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.50
US$14.33
+160.61%
29.23%US$20.00US$10.00n/a3
May ’27US$5.04
US$14.33
+184.39%
29.23%US$20.00US$10.00n/a3
Apr ’27US$6.11
US$14.33
+134.59%
29.23%US$20.00US$10.00n/a3
Mar ’27US$4.56
US$14.33
+214.33%
29.23%US$20.00US$10.00n/a3
Feb ’27US$3.88
US$15.00
+286.60%
33.33%US$20.00US$10.00n/a2
Jan ’27US$3.32
US$15.00
+351.81%
33.33%US$20.00US$10.00n/a2
Dec ’26US$3.82
US$15.00
+292.67%
33.33%US$20.00US$10.00n/a2
Nov ’26US$2.81
US$12.00
+327.05%
49.07%US$20.00US$6.00n/a3
Oct ’26US$2.08
US$12.00
+476.92%
49.07%US$20.00US$6.00n/a3
Sep ’26US$1.71
US$12.00
+601.75%
49.07%US$20.00US$6.00n/a3
Aug ’26US$2.00
US$12.00
+500.00%
49.07%US$20.00US$6.00n/a3
Jul ’26US$1.44
US$12.00
+733.33%
49.07%US$20.00US$6.00n/a3
Jun ’26US$1.73
US$12.00
+593.64%
49.07%US$20.00US$6.00n/a3
May ’26US$1.56
US$13.67
+776.07%
42.39%US$20.00US$6.00US$5.043
Apr ’26US$1.50
US$13.67
+811.11%
42.39%US$20.00US$6.00US$6.113
Mar ’26US$2.27
US$9.80
+331.72%
70.22%US$20.00US$3.00US$4.565
Feb ’26US$3.03
US$17.40
+474.26%
26.61%US$22.00US$9.00US$3.885
Jan ’26US$3.44
US$17.40
+405.81%
26.61%US$22.00US$9.00US$3.325
Dec ’25US$26.91
US$86.33
+220.82%
12.09%US$100.00US$68.00US$3.826
Nov ’25US$47.43
US$79.83
+68.32%
21.70%US$100.00US$54.00US$2.816
Oct ’25US$40.48
US$77.80
+92.22%
23.54%US$100.00US$54.00US$2.085
Sep ’25US$43.48
US$66.00
+51.79%
30.23%US$100.00US$50.00US$1.714
Aug ’25US$37.97
US$62.25
+63.95%
35.38%US$100.00US$45.00US$2.004
Jul ’25US$18.98
US$62.25
+227.98%
35.38%US$100.00US$45.00US$1.444
Jun ’25US$25.50
US$49.67
+94.77%
7.41%US$54.00US$45.00US$1.733
May ’25US$26.54
US$47.50
+78.98%
5.26%US$50.00US$45.00US$1.562
US$14.33
Fair Value
61.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 10:21
End of Day Share Price 2026/05/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q32 Bio Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Imogen MansfieldCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.
Jay OlsonOppenheimer & Co. Inc.